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Health in Action
W
orldwide, Haemophilus 
inﬂuenzae type b (Hib) causes 
at least 3 million cases of 
severe disease each year. Approximately 
400,000 children die annually due to 
pneumonia or meningitis caused by 
Hib [1]. Severe neurological sequelae 
occur in 15% to 30% of those who 
survive Hib meningitis [2]. Other, 
less frequent, manifestations of 
Hib are epiglottitis, septic arthritis, 
osteomyelitis, and septicemia [1–3]. 
Current polysaccharide–protein 
conjugate Hib vaccines are highly 
efﬁcacious and safe. Primary series 
of two or three doses protect 
approximately 95% of infants [4–8]. 
Universal infant Hib immunization 
has proven to dramatically reduce Hib 
invasive disease [9–13] through direct 
vaccine protection and an important 
herd effect related to the reduction 
in Hib nasopharyngeal carriage in 
the community [12,14–16]. Adverse 
events are rare, and Hib vaccine is 
contraindicated only for persons with 
hypersensitivity to any of the vaccine’s 
components [8,17]. 
The World Health Organization 
(WHO) recommends the introduction 
of Hib vaccines worldwide [1]. 
Furthermore, the Global Alliance for 
Vaccines and Immunization (GAVI 
Alliance)—an organization that aligns 
public and private resources in a global 
effort to create greater access to the 
beneﬁts of immunization—considers 
Hib vaccine introduction in the world’s 
poorest countries to be a top priority 
[18].
Prior to vaccine introduction, 
an estimated 20,000 cases of Hib 
meningitis were estimated to occur in 
countries of Latin America and the 
Caribbean (LAC) annually, based on 
an overall Hib meningitis incidence 
of 35 per 100,000 children aged 0–4 
years [19]. Another 20,000 cases of 
invasive Hib disease were estimated 
to occur in the United States annually 
[20]. Most cases occurred in children 
aged less than 24 months, with at least 
60% of cases occurring in children 
aged 0–11 months in half of the 
studies. The annual mortality rate for 
Hib meningitis in children aged less 
than ﬁve years was estimated to be 
around two per 100,000 in the Western 
Hemisphere [21]. 
In this article, we review the progress 
of vaccine introduction, lessons 
learned, and remaining challenges 
regarding Hib vaccination in the 
Americas, with emphasis on LAC 
countries. We expect that this updated 
and summarized information on 
Hib vaccination will serve as a useful 
reference to public health ofﬁcials 
and policy makers from other regions 
who face the challenge of introducing 
Hib and other new or underutilized 
vaccines.
Methods
To assess the progress accomplished by 
LAC countries in Hib vaccination and 
the remaining challenges, we reviewed 
the Pan American Health Organization 
(PAHO)’s Technical Advisory Group 
(TAG) on Vaccine-preventable Diseases 
recommendations; annual country 
immunization reports to PAHO; Hib-
containing vaccine purchase records 
from PAHO’s Revolving Fund; and Hib 
isolation data from selected countries 
participating in a Regional Laboratory 
Network for Surveillance of Bacterial 
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Summary Points
•  Hib vaccine introduction in countries 
of Latin America and the Caribbean 
has substantially reduced morbidity 
and mortality due to invasive Hib 
infections. 
•  All Latin American and Caribbean 
countries but one include Hib vaccine 
in their routine immunization schedule 
for infants.
•  Factors that favored this region-wide 
Hib vaccine adoption include strong 
political will, data supporting Hib 
disease burden and impact in early 
adopting countries, and experience 
exchange among countries. 
•  Financial sustainability when 
introducing the more expensive 
Hib vaccine was critical for ensuring 
successful vaccine introduction in all 
countries.
•  Efforts are still needed to improve 
vaccination coverage and to 
strengthen invasive bacterial disease 
surveillance in developing countries.PLoS Medicine  |  www.plosmedicine.org 0531 April 2008  |  Volume 5  |  Issue 4  |  e87
Meningitis and Pneumonia (Sistema 
Regional de Vacunas, or SIREVA). We 
examined data from 1997 to 2006.
PAHO is an international public 
health agency with more than 100 
years of experience in working to 
improve health and living standards 
of the countries of the Americas. 
PAHO serves as the WHO Regional 
Ofﬁce for the Americas, and provides 
technical assistance to all countries and 
territories in the Western Hemisphere. 
However, most of PAHO’s technical 
cooperation is targeted to the poorer 
countries of LAC [22]. PAHO’s TAG 
is comprised of eight immunization 
and vaccine experts who meet 
biennially, in the presence of Member 
States’ immunization representatives, 
to provide recommendations on 
vaccination policy and strategies to 
improve countries’ vaccination efforts 
[22].
Since the 1980s, Member States 
submit annual immunization reports to 
PAHO, using a standardized form, the 
PAHO-WHO/UNICEF Joint Reporting 
Form (previously known as EPI tables). 
This form includes data on:
•  all routine vaccines included in  
  country immunization schedules; 
• vaccine  presentation; 
•  annual administrative coverage rates  
  (for Hib, number of third doses  
  of Hib vaccine given divided by the  
  number of children aged less than  
 one  year); 
•  surveillance data (i.e., number of  
  Hib meningitis cases);
•  immunization ﬁnancing indicators,  
  such as the percentage of all routine  
  vaccine expenditures ﬁnanced with  
  government funds (this excludes any  
  external ﬁnancing from donors, but  
  may include loans); 
•  existence of a budget line for vaccine   
 purchase;  and
•  existence of immunization-related  
 legislation. 
The Revolving Fund (RF) is the 
mechanism for bulk purchase of 
vaccines and immunization supplies, 
managed by PAHO, since 1979, to 
serve Member States. PAHO annually 
consolidates vaccine orders from 
countries that wish to participate and 
conducts an international bid open 
to all vaccine manufacturers. PAHO 
procures vaccines with money drawn 
from the RF, and countries reimburse 
the RF for purchases made on their 
behalf [23,24].
SIREVA was started in 1993 
to monitor the distribution of 
pneumococcal serotypes causing 
severe disease and the antimicrobial 
resistance patterns of pneumococci in 
six countries. Subsequently, SIREVA 
expanded its mandate to conduct 
laboratory surveillance for other agents 
that cause meningitis and pneumonia, 
such as Hib and meningococcus. 
PAHO Recommendations 
Regarding Hib Immunization
To control Hib invasive disease and 
reduce Hib carriers in the Americas, 
PAHO’s TAG recommends, since 1997, 
that Member States:
•  introduce Hib vaccine into the  
  routine universal infant  
 immunization  schedule; 
•  establish sustainable ﬁnancial  
  mechanisms to maintain vaccination  
  against Hib; and
•  monitor and report vaccination  
  coverage and Hib cases in order to  
  evaluate the impact of the  
 intervention.
To help ensure sustainability 
of Hib vaccination, TAG has also 
recommended purchasing Hib vaccine 
in combination with diphtheria-
tetanus-pertussis vaccine (DTP) or 
DTP/hepatitis B vaccine through the 
RF, as this can result in signiﬁcant cost 
savings. 
Progress in Hib Vaccine 
Introduction
By the end of 2006, all countries of the 
Americas, except Haiti, had included 
Hib in their infant immunization 
schedule (Table 1). As a result, 
over 98% of the 16 million children 
born annually in the Americas live 
in countries routinely using Hib-
containing vaccines. Canada (1986) 
and the United States (1991) were 
among the ﬁrst countries to introduce 
Hib vaccine. Bermuda (1989), the 
Cayman Islands (1992), and the 
Dutch territories (1995) were ﬁrst in 
the Caribbean. Uruguay and Chile 
followed in 1994 and 1996, respectively. 
Uruguay conducted an aggressive 
catch-up introduction of Hib vaccine 
for all children aged one to four years, 
whereas Chile started vaccinating 
one birth cohort at a time [11,25]. 
Argentina followed in 1997. However, 
most countries and territories (n = 20) 
introduced Hib vaccine between 1998 
and 2000, more than ten years after the 
vaccine was ﬁrst licensed in 1987. In 
2006, Dominica was the last country to 
introduce Hib vaccine. 
Most countries include only three 
doses for children aged less than one 
year. However, Canada, the French 
Departments and the Dutch territories 
in the Caribbean, the United States, 
and eight LAC countries and territories 
include a booster dose during the 
second year (Table 1). 
In most countries, Hib vaccination 
was introduced nationwide. Due mostly 
to limited resources, countries such as 
Brazil, Guatemala, and Peru started 
vaccinating in selected populations 
or geographical areas. The use of Hib 
vaccine through the private sector 
in the region, in some cases years 
before introduction into the regular 
immunization program, has been 
widespread, but not quantiﬁed [11].
Lessons Learned
Logistics. One of the lessons learned 
with Hib vaccine introduction in the 
Americas is that the selection of a 
vaccine formulation (combination 
versus monovalent) and presentation 
(one- versus ten-dose vials) is essential. 
It has an impact on the price, vaccine 
wastage percentage, cold chain space, 
need for reconstitution, and training 
activities for health care workers 
[11,25,26]. 
Currently, 34 countries use Hib in 
the form of a DTP-Hib-hepatitis B 
combination vaccine, or pentavalent 
(only available in one-dose vials) (Table 
1). Of 17 countries and territories that 
started using monovalent Hib vaccine, 
only Canada and the United States 
have not switched to a combination 
vaccine, although in both countries, 
Hib combinations are often available as 
alternatives. 
Hib vaccine in a combination 
formulation offers several advantages. 
Combination vaccines reduce the 
number of injections, thereby lowering 
the risk of injection complications and 
adverse events and reducing missed 
vaccination opportunities. In addition, 
parents and health care workers show 
greater acceptance of combination 
vaccines [27,28]. Combination Hib 
vaccine tends to be less expensive 
than monovalent Hib vaccine, thus 
contributing to the sustainability of 
immunization programs [27,28–30]. 
Financing Hib vaccination. Although 
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is highly cost-beneﬁcial in both 
developed and developing settings 
[31–33], Hib vaccine price is higher 
than the traditional vaccines of the 
Expanded Program on Immunization 
(EPI). The price of Hib vaccine is 
more than double the measles-mumps-
rubella vaccine, the most expensive 
among the traditional EPI vaccines 
(US$3.15 versus US$1.4 per dose). 
Therefore, ﬁnancial sustainability 
has been a critical consideration for 
Table 1. Hib Vaccination in the Americas, 1991–2007
Country/Territory Year Hib 
Introduced
Vaccine Used 
When Introduceda
Vaccine used in 
2007a
Routine Childhood Schedule 2007
1st Dose 2nd Dose 3rd Dose Booster
Anguilla 1998 Hib Pentavalent  3 m 5 m 7 m  
Antigua & Barbuda 2000 Pentavalent Pentavalent 2 m 4 m 6 m  
Argentina 1997 DTP-Hib DTP-Hib 2 m 4 m 6 m 18 m
Bahamasb 1998 Hib Pentavalent 2 m 4 m 6 m  
DTP-Hib 15 m
Barbadosb 2000 Pentavalent Pentavalent 3 m 4.5 m 6 m
Belize 2001 DTP-Hib Pentavalent 2 m 4 m 6 m  
Bermuda 1989 Hib DTaP-IPV-Hib 2 m 4 m 6 m 15–18 m
Bolivia   2000 Pentavalent Pentavalent 2 m 4 m 6 m  
Brazil 1999 Hib DTP-Hib 2 m 4 m 6 m  
British Virgin Islands 1999 Hib Pentavalent 2 m 4 m 6 m  
Canadac 1986  Hib Hib or DTaP-IPV-Hib 2 m 4 m 6 m 18 m
Cayman Islands 1992 Hib DTaP-IPV-Hib 2 m 4 m 6 m  
DTaP-Hib 15 m
Chile 1996 Hib/ DTP-Hib Pentavalent 2 m 4 m 6 m  
Colombia 1998 Hib Pentavalent 2 m 4 m 6 m
Costa Rica 1998 Hib Pentavalent 2 m 6 m  
Hib 4 m   15 m 
Cuba 1999 Hib Pentavalent 2 m 4 m 6 m
Hib 18 m
Dominicad 2006 Pentavalent Pentavalent  2 m 4 m 6 m  
Dominican Republic 2001 Pentavalent Pentavalent 2 m 4 m 6 m
Ecuador 2003 Pentavalent  Pentavalent 2 m 4 m 6 m
El Salvador 2002 Pentavalent  Pentavalent 2 m 4 m 6 m  
Grenada 2000 Pentavalent  Pentavalent 6–8 w 16–20 w 24–28 w  
Guatemalae 2005 Pentavalent  Pentavalent 2 m 4 m 6 m  
Guyana 2001 Pentavalent  Pentavalent 2 m 4 m 6 m  
Haiti Not introduced
Honduras 1999 Hib Pentavalent 2 m 4 m 6 m  
Jamaica 2003 Pentavalent  Pentavalent 6 w 3 m 5–6 m  
Mexico 1998 Pentavalent  Pentavalent 2 m 4 m 6 m  
Montserrat  1999 Hib Pentavalent 2 m 4 m 6 m
Nicaragua 1999 Pentavalent  Pentavalent 2 m 4 m 6 m  
Panama 2000 Pentavalent  Pentavalent 2 m 4 m 6 m
DTP-Hib    18  m
Paraguay 2002 Pentavalent  Pentavalent 2 m 4 m 6 m  
Peruf 2005 Pentavalent  Pentavalent 2 m 4 m  
Hib 3 m
St. Kitts & Nevis 2000 Pentavalent Pentavalent 2 m 4 m 6 m  
St. Lucia 2002 Pentavalent Pentavalent 3 m 5 m 7 m  
St. Vincent & Grenadines 2003 Pentavalent Pentavalent 2 m 4 m 6 m
Suriname 2005 Pentavalent Pentavalent 2 m 4 m 6 m
Trinidad & Tobago 1999 Hib Pentavalent 3 m 4–5 m 6 m  
Turks & Caicosg 1999 Hib Pentavalent 2 m 4 m 6 m  
Uruguay 1994 Hib Pentavalent 2 m 4 m 6 m 12 m
United Statesh  1991 Hib Hib or combination 2 m 4 m 6 m 12–15 m
Venezuela 2000 Hib Pentavalent 2 m 4 m 6 m  
Source: Country Reports to PAHO, unless otherwise stated. Territories not routinely reporting to PAHO—French Guiana, Guadeloupe, Martinique, Aruba, and the Netherlands 
Antilles—include Hib in their routine infant immunization schedule (not shown). 
aHib refers to monovalent Hib vaccine; pentavalent to combination DTP-Hib-hepatitis B vaccine. 
bSchedule obtained from WHO Vaccine-Preventable Diseases: Monitoring System. WHO, 2004.
cPolysaccharide vaccine Hib for children aged ≥24 months introduced in 1986. Hib conjugated vaccines for infants introduced in 1992. 
dThe country has purchased pentavalent vaccine for introduction in late 2006.
ePentavalent vaccine introduced for the social security beneﬁciaries in 1999 (Instituto Guatemalteco del Seguro Social). Introduced in 2005 for the rest of the country.
fStarted using Hib vaccine in parts of the country as early as 1997, but Hib vaccine became part of the schedule for the entire country only in 2005. 
gSchedule changed in 2006 from pentavalent at 6, 12, and 18 weeks.
hCombination DTaP-hepatitis B-IPV and Hib-hepatitis B may be offered as options. Schedule obtained from CDC Web site at: http://www.cdc.gov/nip/recs/child-schedule.htm.
IPV, inactivated polio vaccine; m, months; w, weeks; y, years.
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countries introducing Hib vaccination 
into their routine immunization 
schedule. To ensure sustainability, 
PAHO recommends purchasing Hib 
vaccine in combination with DTP 
or DTP/hepatitis B vaccine through 
the PAHO RF, and advocates for 
countries to issue legislation ensuring 
a budget line for vaccine purchase and 
other expenses of the immunization 
program. 
In 2006, all but three of the LAC 
countries using Hib (Bolivia, the 
Dominican Republic, and Nicaragua) 
ﬁnanced more than 95% of their 
public sector routine vaccine expenses 
using government funds. Also, in most 
LAC countries (27 of 31 with data 
available) at least 90% of the national 
immunization program’s recurring 
costs were ﬁnanced using government 
funds. All LAC countries using Hib 
vaccine have reported having a 
budget line for vaccine purchase (the 
Dominican Republic, Jamaica, and 
Saint Kitts and Nevis include vaccines 
in a budget line for medication 
purchase). 
Of the six GAVI-eligible countries in 
LAC (countries with a gross national 
income of less than US$1,000 per 
capita), Guyana was the only one to 
introduce Hib vaccine (as pentavalent) 
using GAVI support. In 2006, Guyana 
took over the full ﬁnancing of this 
vaccine. Other low-income countries 
have introduced pentavalent with 
support from other aid agencies. 
As of 2006, 26 LAC countries 
reported having some immunization-
related legislation, and three more 
were in the process of adopting such 
laws. In countries with legislation, laws 
and decrees have been used as a way 
to secure a budget line for vaccines 
and sustain vaccine introduction [34]. 
Among the Hib vaccine early adopters, 
Hib introduction followed ministerial 
and presidential decrees in Chile 
and Uruguay [25]. No information 
regarding the speciﬁc relation 
between Hib vaccine introduction 
and legislation is available for other 
countries. 
Maintaining affordable prices is 
critical for vaccine introduction. 
The price of Hib vaccine purchased 
through the RF started at between 
US$6 and US$8.2 per dose in 1997 
and dropped markedly, to between 
US$2.18 and US$2.60, at the end of 
1998, as signiﬁcantly more doses were 
purchased. For 2007, the RF price is 
US$3.15 per dose of the combination 
DTP-Hib (ten-dose vials) and US$3.92 
per dose of pentavalent (one-dose 
vials). 
In 2006, all LAC countries but four 
procured Hib-containing vaccines 
through the RF: two used Hib-
containing vaccines produced in their 
own countries (Brazil and Cuba) and 
two purchased directly from a vaccine 
manufacturer. 
Regional laboratory network. 
Having a regional laboratory network 
has been instrumental in monitoring 
the circulating Hib strains that 
cause bacterial meningitis and 
pneumonias. As of 2006, SIREVA 
included laboratories from 19 
Latin American countries plus the 
Caribbean Epidemiology Centre, and 
continued to monitor trends in the 
circulating serotypes and antimicrobial 
resistance patterns of Hib, as well as 
pneumococcus and meningococcus 
[35]. 
Remaining Challenges
Hib vaccination coverage. PAHO 
recommends reaching coverage levels 
of at least 95% for all vaccines in all 
municipalities [36,37]. Throughout the 
past seven years, the overall reported 
administrative coverage (weighted 
average) with three doses of Hib 
vaccine (Hib3) in LAC has increased 
from 78% in 2000 to 94% in 2006 
(with 19 and 37 countries reporting, 
respectively). However, the lower 
coverage reported in earlier years 
mostly reﬂects the partial use of Hib 
vaccine during the year of introduction. 
Hib3 coverage rates are comparable 
to those observed for the third dose 
of the diphtheria-tetanus-pertussis 
vaccine (DTP3). Use of combination 
vaccines contributes to this ﬁnding. No 
deterioration in DTP3 coverage during 
the year of Hib vaccine introduction 
is apparent from the coverage data 
available. 
Coverage varies between and within 
countries. In 2006, reported coverage 
ranged from 83% to greater than 
100%. Also, 42% of LAC municipalities 
(districts) reported coverage levels 
below 95%, using DTP3 as a proxy 
for Hib3. This ﬁnding illustrates that 
inequities in Hib vaccine use still exist 
in LAC countries. 
Sustainability of immunization 
programs. A major challenge 
for countries of the Americas is 
maintaining Hib vaccination while 
adding new, more expensive vaccines 
into national routine schedules. PAHO 
is currently developing a regional policy 
framework to assist countries in the 
following areas: exploring mechanisms 
to ﬁnd new approaches for sustainable 
ﬁnancing, focusing on securing 
longer-term and reliable funding for 
immunization programs, particularly 
through the creation of ﬁscal space; 
strengthening vaccine legislation to 
reduce national transaction costs; and 
improving the efﬁciency of the RF and 
expanding participation in its services 
to ensure that countries can afford new-
generation vaccines [34,37–39].
“Creating ﬁscal space” is an 
expression used for mobilizing 
additional resources without 
compromising existing priorities in 
health. Mechanisms used include: 
identifying new partners; enhancing 
tax collection procedures; raising 
additional revenues through national 
lotteries, as was done for new vaccine 
purchase in Costa Rica; and exempting 
vaccine purchases from import tax, 
since import taxes can raise the vaccine 
purchase cost by as much as 30% in 
some countries. 
PAHO recently described model 
vaccine legislation based on an analysis 
of existing laws [34]. Some of the 
legislation components aim to secure 
resources for immunization programs 
and include: a budget line for vaccines; 
regulations guaranteeing timely and 
reliable disbursement of resources; 
tax exemptions for vaccines and 
immunization supplies; ﬂexibility to 
contract with suppliers, including third 
parties such as the RF; and streamlined 
customs regulations to accelerate 
the importation process and reduce 
transaction costs. 
Vaccination impact. The impact of 
Hib vaccine introduction has been 
well documented by reductions in Hib 
meningitis in selected countries of the 
Americas [9–11,25,40]. However, some 
countries are still lacking a surveillance 
of bacterial invasive disease that 
performs sufﬁciently well to document 
such impact. 
A decrease in Hib meningitis has 
been well documented in Chile, 
Colombia, and Uruguay, in spite of 
differences in the introduction strategy 
and the coverage levels attained 
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reached coverage levels of greater than 
90% since vaccine introduction, but 
only Uruguay had an aggressive catch-
up strategy at vaccine introduction. 
The schedule in Uruguay calls for a 
booster dose at 12 months. Colombia 
initially achieved moderate coverage 
levels (50%–65%) that have increased 
to more than 86% over the last 
three years. Based on coverage levels 
achieved, 95% vaccine effectiveness, 
and the 20,000 cases estimated in the 
pre-vaccine era [19], PAHO estimates 
that Hib meningitis cases in LAC have 
decreased by approximately 85%. 
In recent years, the number of Hib 
isolates from children aged less than 
two years has decreased in selected 
countries, from 92 in 2000 to 30 in 
2005 in Brazil, from 30 in 2000 to 
eight in 2005 in Colombia, from 
53 in 2000 to four in 2005 in the 
Dominican Republic, and from 44 in 
2000 to two in 2005 in Venezuela. In 
these four countries, the number of 
pneumococci and menigococci isolates 
has remained stable over the same time 
period [35]. Hib isolates continue to 
be obtained from countries using Hib 
vaccine. However, neither SIREVA 
nor PAHO routinely collect data on 
the vaccination status of Hib cases 
reported.
Only a few LAC countries have been 
able to demonstrate that Hib vaccine 
has been effective against pneumonia 
in children aged less than two years. 
Hib vaccine has reduced the incidence 
of hospitalized pneumonia by about 
20% in Chile [41,42]. For radiologically 
diagnosed pneumonia, vaccine 
effectiveness has been estimated at 
31% in central Brazil and up to 55% 
in a case-control study conducted in 
Colombia [43,44]. 
Hib surveillance remains one of the 
most important challenges in LAC. To 
promote the strengthening of routine 
surveillance, PAHO recommends the 
integration of Hib into the routine 
surveillance of bacterial meningitis 
and pneumonias [3]. As done in the 
Central American sub-region, this 
will require adapting WHO’s generic 
protocol for population-based Hib 
surveillance [3,45,46]. Currently, 
case deﬁnitions and surveillance 
procedures vary by country, limiting 
data comparability. 
Monitoring the effectiveness of Hib 
vaccine in the routine immunization 
program is essential because vaccine 
efﬁcacy may be affected by several 
factors, such as the use of booster 
doses, waning immunity, reduction of 
natural boosting due to reduced Hib 
transmission [47], and cold damage in 
storage units not maintained properly. 
Monitoring the changing epidemiology 
of H. inﬂuenzae disease in the post-
vaccine era will also be important, 
as the role of invasive non-b type H. 
inﬂuenzae may become prominent 
[48]. The importance of continued 
Hib disease monitoring has been 
recently highlighted. In the United 
Kingdom, an unexpected increase in 
the incidence of Hib disease coincided 
doi:10.1371/journal.pmed.0050087.g001 
Figure 1. Coverage with Third Dose of Vaccine Containing Hib in Children Aged Less Than One Year and Number of Reported Hib Meningitis 
Cases by Year in Chile, Colombia, and Uruguay 
Source: Country reports to PAHO and XVI Meeting of PAHO’s TAG, 2004. No Hib meningitis data were reported to PAHO from Colombia for 2002, and 
zero cases were reported from Uruguay in 2006.PLoS Medicine  |  www.plosmedicine.org 0535 April 2008  |  Volume 5  |  Issue 4  |  e87
with the distribution of combination 
vaccines that contain acellular pertussis 
(diphtheria-tetanus-acellular pertussis-
Hib vaccine, or DTaP-Hib) [49–52]. 
In the Gambia, Hib seems to have re-
appeared in 2005–2006 after at least 
three years with no cases [53].
The added value of using a booster 
dose has been debated extensively 
because the majority of Hib disease 
burden in developing countries occurs 
before the age when the booster is 
usually administered (12–18 months) 
[1]. PAHO is currently assisting four 
countries to determine whether a 
booster dose during the second year of 
life is useful. 
Efforts are in place to enhance 
the work done by SIREVA, 
including collecting more clinical 
and epidemiological data. This 
new initiative, known as “Network 
Surveillance System for the Bacterial 
Agents Responsible for Pneumonia 
and Meningitis” or SIREVA II, should 
provide a better understanding of 
the occurrence of cases in countries 
reporting high Hib coverage and the 
possibility of serotype replacement over 
time. 
Conclusions
Although LAC countries lagged 
behind North America in their efforts 
to introduce Hib vaccine into their 
childhood immunization schedules, 
probably due mostly to ﬁnancial 
considerations, all but Haiti had 
introduced this vaccine by the end of 
2006. Even though the data available 
regarding Hib is not complete and 
comes from routine reporting by 
countries to PAHO, we believe that 
the main factors that favored the 
region-wide adoption of Hib vaccine 
in LAC are the safety and effectiveness 
of conjugated Hib vaccines; strong 
political will; the existence of data 
supporting a high Hib disease burden 
and vaccination impact in early 
adopters, and their lessons learned, 
shared through several publications 
and regional meetings; and PAHO’s 
efforts to ensure the affordability of 
Hib vaccines, mainly through the RF. 
Striving to use Hib in combination 
with other antigens and considering 
mechanisms to ensure sustainability, 
such as vaccine laws or presidential 
decrees whenever possible, will 
accelerate introduction. The main 
challenges remaining in LAC countries 
are to address low vaccination coverage 
in low-performing districts, ensure Hib 
vaccination while introducing other 
new and more expensive vaccines, 
and establish or strengthen Hib 
surveillance, better utilizing the well-
established laboratory network. When 
considering the introduction of other 
new vaccines, LAC countries must take 
into account lessons learned from Hib 
introduction, in order to shorten the 
lag between vaccine development and 
widespread adoption in developing 
countries.  
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